A new melanoma drug that tricks the body into destroying cancer cells is keeping patients alive for years longer than expected, with some researchers calling the breakthrough in immunotherapy a “penicillin moment” in cancer treatments.
SOURCE: Medical Research – Read entire story here.
Related posts:
- Governments take decisive step towards more affordable vaccines Governments meeting in Geneva for the annual World Health Assembly raised the alarm on Monday over the exorbitant rise in the price to vaccinate a child, passing a resolution urging more affordable... ...
- SDSU researchers awarded NIH grant to understand how autism plays out across the lifespan In the public consciousness, autism spectrum disorder only affects children. In truth, ASD is a lifelong condition. But how it affects older adults is a gaping unknown in autism research. Now, a new and significant grant from the National Institutes of Health will help researchers at San Diego State University understand how the disorder plays out across the lifespan. ...
- Tasmanian Government urged to ensure medicinal cannabis available to patients The Tasmanian Opposition calls on Government to ensure medicinal cannabis becomes available for patients. ...
- Portable finger-probe device can successfully measure liver function in potential organ donors A portable, finger-probe device successfully measured liver function in brain dead adult organ donors, a finding that could change the way organs are assessed and save thousands of dollars per transplant, a study has found. ...
- Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences--and so preventing mutations--are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability. ...
